FDA has approved Tecvayli for relapsed or refractory multiple myeloma

The Food and Drug Administration ( FDA ) has granted accelerated approval to Tecvayli ( Teclistamab-cqyv; Teclistamab ), the first ...

Leggi articolo

Daprodustat in treatment of anaemia associated with chronic kidney disease

The treatment of anaemia associated with chronic kidney disease with Daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor ( ...

Leggi articolo

Blinatumomab has demonstrated significantly prolonged event-free survival compared with consolidation chemotherapy in pediatric patients with relapsed acute lymphoblastic leukemia

Data from a multicenter, randomized phase 3 study ( 20120215 ) evaluating the efficacy, safety and tolerability of Blinatumomab ( ...

Leggi articolo

Benefits of maintenance Atezolizumab in extensive-stage small cell lung cancer: IMpower133

The latest analysis from the IMpower133 trial has demonstrated continued improvement in outcomes for patients with extensive-stage small cell lung ...

Leggi articolo

Margenza based on Margetuximab for metastatic HER2-positive breast cancer. FDA has approved

The Food and Drug Administration ( FDA ) has approved Margetuximab-cmkb ( Margetuximab; Margenza ) in combination with chemotherapy, for ...

Leggi articolo

Tomivosertib added on to continued checkpoint inhibitor therapy

Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response represents a major ...

Leggi articolo

PRESTO trial: nurse preferences between Lanreotide Autogel new syringe and Octreotide long-acting release current syringe in management of neuroendocrine tumors and acromegaly

PRESTO study has been presented at the 17th European Neuroendocrine Tumor Society ( ENETS ) Annual Conference. PRESTO was a multi-national, ...

Leggi articolo

Expansion of Trulicity label to include results from REWIND cardiovascular and diabetes outcomes trial

The European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) issued a positive opinion recommending an ...

Leggi articolo

Nintedanib in patients across a range of progressive fibrosing interstitial lung diseases

Progressive fibrosis of the lung can have a devastating impact on patients with a range of conditions. Except for idiopathic ...

Leggi articolo

Hepatitis C drugs reduce liver-related deaths by nearly half

A new study from the UT Southwestern Simmons Comprehensive Cancer Center has demonstrated that antiviral drugs for hepatitis C reduce ...

Leggi articolo

PRIMA trial: Niraparib has demonstrates significant improvement in progression free survival for women regardless of their biomarker status, with ovarian cancer in the first line maintenance setting

Positive results from PRIMA ( ENGOT-OV26/GOG-3012 ) were announced. PRIMA is a phase 3 randomized, double-blind, placebo-controlled, study of Niraparib ...

Leggi articolo

Venetoclax as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukemia patients

In April 2016, the U.S. FDA ( Food and Drug Administration ) first granted accelerated approval of Venclexta ( Venetoclax ...

Leggi articolo

Belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment

A study has reported long-term health-related quality of life ( HRQoL ) and fatigue outcomes in patients with systemic lupus ...

Leggi articolo

New therapies for multiple myeloma: Daratumumab, Elotuzumab, Ixazomib

At the 57th American Society of Hematology ( ASH ) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer ...

Leggi articolo

Eravacycline for the treatment of complicated intra-abdominal infections and complicated urinary tract infections

The following key attributes of Rravacycline, observed in clinical trials and preclinical studies of Eravacycline, differentiate Eravacycline from other antibiotics ...

Leggi articolo

Human proprotein convertase subtilisin/kexin type 9 monoclonal antibodies: safety and efficacy of Alirocumab 150 mg every 2 weeks

Alirocumab ( Praluent ), a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 [ PSCK9 ], is in ...

Leggi articolo

CHMP has recommended Sjnjardy, a combination of Empagliflozin and Metformin HCL, for patients with type 2 diabetes mellitus

Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has recommended ...

Leggi articolo

Autoimmune thyroid diseases and vitamin D

Vitamin D deficiency ( levels lower than 20 ng/ml ) is becoming a global health problem, since it is increasingly ...

Leggi articolo

Vadadustat, a potentially novel approach to treat anemia related to chronic kidney disease in patients who are not dependent on dialysis

Data on Vadadustat ( AKB-6548 ) were presented at the 2014 European Renal Association - European Dialysis and Transplant Association ...

Leggi articolo

CONNECT trial: cognitive performance in adult patients treated with Vortioxetine for major depressive disorder

The results from CONNECT, a new study that has evaluated the effect of Vortioxetine ( Brintellix ) 10-20 mg/d on ...

Leggi articolo

Female patients with acne and the triad of cutaneous hyperandrogenism: the efficacy of oral Isotretinoin versus Cyproterone

SAHA ( Seborrhea, Acne, Hirsutism and Androgenetic Alopecia ) syndrome is a dermatologic disorder, with variant response to treatment. Triad ...

Leggi articolo

Vitamin D supplementation decreases diffuse musculoskeletal pain

Several studies have shown that vitamin D supplementation could be useful for treating diffuse musculoskeletal ( DMS ) pain in ...

Leggi articolo

Patients with moderately to severely active ulcerative colitis: 4-year maintenance treatment with Humira

The safety and efficacy of Adalimumab ( Humira ) for patients with moderately to severely active ulcerative colitis has been ...

Leggi articolo

COPD: Tiotropium plus Olodaterol Respimat fixed-dose combination has shown lung function benefits

Boehringer Ingelheim has announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of Tiotropium ...

Leggi articolo

FDA is investigating risk of cardiovascular events with Testosterone products

The FDA ( Food and Drug Administration ) is investigating the risk of stroke, myocardial infarction, and death in men ...

Leggi articolo

Pembrolizumab, an investigational anti-PD-1 immunotherapy, in previously-treated patients with non-small cell lung cancer

Interim data from a phase 1B trial ( PN001 ) evaluating Pembrolizumab ( MK-3475 ), an investigational anti-PD-1 immunotherapy, in ...

Leggi articolo

Combination of HCV therapies Grazoprevir and Elbasvir: sustained virologic response at post-treatment follow-up week 12 seen in 100% of patients in two of the three combination arms studied

Interim data from the ongoing C-WORTHY study, a phase II clinical trial evaluating the efficacy and safety of an all-oral ...

Leggi articolo

Serelaxin improves symptoms and mortality across multiple subgroups of patients with acute heart failure

Results from a new analysis of the phase III RELAX-AHF study published in the European Heart Journal and presented at ...

Leggi articolo

Brintellix for the treatment of adults with major depressive episodes, approved by European Commission

The European Commission granted marketing authorization for Brintellix ( Vortioxetine ) for the treatment of adults with major depressive episodes. ...

Leggi articolo

Tretten to treat congenital Factor XIII A-subunit deficiency, a rare genetic clotting disorder, FDA approved

The FDA ( Food and Drug Administration ) has approved Tretten, coagulation Factor XIII A-subunit ( recombinant ), the first ...

Leggi articolo

CHMP positive opinion for Cimzia in active psoriatic arthritis

The European Medicines Agency’s ( EMA’s ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a ...

Leggi articolo

Olysio, a new therapy to treat chronic hepatitis C virus infection, approved by FDA

Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or ...

Leggi articolo

Nexavar to treat metastatic differentiated thyroid cancer, FDA approved

The FDA ( Food and Drug Administration ) has expanded the approved uses of Nexavar ( Sorafenib ) to treat ...

Leggi articolo

Kadcyla for advanced HER2-positive breast cancer, approved in EU

Roche has announced that Kadcyla ( Trastuzumab emtansine or T-DM1 ) has been approved by the European Commission for people ...

Leggi articolo

EU: Xofigo for adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, approved

Bayer HealthCare has announced that the European Commission ( EC ) has granted marketing authorisation for Xofigo 1000 kBq/ml, solution ...

Leggi articolo

Dipeptidyl peptidase-4 inhibitors may also reduce the risk of autoimmune diseases in patients with type 2 diabetes

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the ...

Leggi articolo

FDA: safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics

The Food and Drug Administration ( FDA ) has announced class-wide safety labeling changes and new postmarket study requirements for ...

Leggi articolo

Abraxane for metastatic pancreatic cancer, FDA approved

The Food and Drug Administration ( FDA ) has expanded the approved uses of Abraxane ( Paclitaxel protein-bound particles for ...

Leggi articolo

Adempas to treat pulmonary hypertension, FDA approved

The Food and Drug Administration ( FDA ) has approved Adempas ( Riociguat ) to treat adults with two forms ...

Leggi articolo

Multiple sclerosis: European Commission has approved Lemtrada

Genzyme has announced that the European Commission ( EC ) has granted marketing authorization for Lemtrada ( Alemtuzumab ). Lemtrada is ...

Leggi articolo

Alzheimer's disease dementia: diuretics, sartans and ACE inhibitors have shown to decrease risk

A Johns Hopkins-led analysis of data previously gathered on more than 3,000 elderly Americans strongly suggests that taking certain blood ...

Leggi articolo

Patients with heart failure: Digoxin linked to higher risk of mortality

Digoxin, a drug commonly used to treat heart conditions, was associated with a 72% higher rate of death among adults ...

Leggi articolo

Perjeta for neoadjuvant breast cancer treatment, FDA approved

The FDA ( Food and Drug Administration ) has granted accelerated approval to Perjeta ( Pertuzumab ) as part of ...

Leggi articolo

Kadcyla for the treatment of adult patients with HER2+, unresectable locally advanced or metastatic breast cancer

The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of ...

Leggi articolo

Inflectra the first biosimilar monoclonal antibody to be approved in Europe

Hospira has announced the European Commission ( EC ) approval of Inflectra ( Infliximab ), Europe's first biosimilar monoclonal antibody ...

Leggi articolo

Dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation

The FDA ( Food and Drug Administration ) has approved Dabrafenib ( Tafinlar capsule ), for the treatment of patients ...

Leggi articolo

Mirvaso for the facial erythema of rosacea, FDA approved

Galderma Laboratories has announced that the FDA ( Food and Drug Administration ) has approved Mirvaso ( Brimonidine ) topical ...

Leggi articolo

FDA breakthrough therapy designation for Bimagrumab for sporadic inclusion body myositis

The FDA ( Food and Drug Administration ) has granted breakthrough therapy designation to Bimagrumab for sporadic inclusion body myositis ...

Leggi articolo

Ruxolitinib in patients with refractory metastatic pancreatic cancer

Incyte has announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of Ruxolitinib ( Jakafi ), its ...

Leggi articolo

High blood levels of Omega-3 fatty acids associated with increased risk of aggressive prostate cancer

A second large, prospective study by researchers at Fred Hutchinson Cancer Research Center ( Seattle; United States ) has confirmed ...

Leggi articolo

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( ...

Leggi articolo

Treatment of metastatic colorectal cancer: Stivarga approved in the European Union

Bayer HealthCare has announced that the European Commission has approved Stivarga ( Regorafenib ) tablets for the treatment of adult ...

Leggi articolo

European Commission has approved Aubagio for multiple sclerosis treatment

Sanofi and its subsidiary Genzyme have announced that the European Commission has granted marketing authorization for Aubagio ( Teriflunomide ) 14 ...

Leggi articolo

GLYX-13 rapidly lifts depression without side effects

GLYX-13, a molecular cousin to Ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded ...

Leggi articolo

Risk of leukemia after cancer chemotherapy

While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients ...

Leggi articolo

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib ...

Leggi articolo

Radium-223 has reduced the risk of death by 30.5% in castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease

Bayer HealthCare has announced that the New England Journal of Medicine ( NEJM ) has published results from Phase III ...

Leggi articolo

Minor or transient stroke: the combination of two anti-clotting drugs, Clopidogrel and Acetylsalicylic acid, reduces the risk of stroke

Results of a phase III clinical trial has shown that a simple drug regimen of two anti-clotting drugs, Clopidogrel ( ...

Leggi articolo

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, ...

Leggi articolo

Xarelto for secondary prevention after an acute coronary syndrome, approved in European Union

Xarelto ( Rivaroxaban ), a novel oral anticoagulant, has been approved by the European Commission ( EC ) for the ...

Leggi articolo

Castration-resistant prostate cancer: significant overall survival benefit observed with Radium 223

Bayer HealthCare has announced that data from the pivotal Phase III ALSYMPCA ( ALpharadin in SYMptomatic Prostate CAncer ) trial ...

Leggi articolo

Sorafenib has shown success in advanced differentiated thyroid cancer patients

The cancer drug Sorafenib ( Nexavar ) holds metastatic thyroid cancer at bay for nearly twice as long as a ...

Leggi articolo

Patients with lung cancer who carry specific HER2 mutations may benefit from certain anti-HER2 drugs

New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ...

Leggi articolo

Addition of Bevacizumab to initial treatment for glioblastoma does not improve patient overall survival or progression-free survival

Glioblastoma is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average ...

Leggi articolo

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a ...

Leggi articolo

MGN1703, an immune-boosting colorectal cancer drug, shows promise

Final data from IMPACT study provide proof of principle for new treatment approach. The findings confirm the biological action of ...

Leggi articolo

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( ...

Leggi articolo

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults ...

Leggi articolo

SAVOR-TIMI-53 Cardiovascular Outcomes Trial: Onglyza does not effect on composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke

Bristol-Myers Squibb ( BMS ) and AstraZeneca have announced top line results of the phase 4 SAVOR-TIMI-53 ( Saxagliptin Assessment ...

Leggi articolo

TRINOVA-1 trial: Trebananib in recurrent ovarian cancer study meets primary endpoint of progression-free survival

Amgen has announced that the Phase 3 TRINOVA-1 trial evaluating Trebananib plus Paclitaxel versus placebo plus Paclitaxel in recurrent ovarian ...

Leggi articolo

RoActemra approved in European Union to treat children with juvenile idiopathic polyarthritis

Roche has announced that the European Medicines Agency ( EMA ) has approved RoActemra ( Tocilizumab ) to treat children ...

Leggi articolo

Rheumatoid arthritis: fewer discontinuations due to adverse events, serious adverse events, serious infections in patients treated with Abatacept plus Methotrexate

Year 2 data has shown similar efficacy between Abatacept ( Orencia ) plus Methotrexate ( MTX ) and Adalimumab ( ...

Leggi articolo

The long-term effects of Epratuzumab in systemic lupus erythematosus: no new safety or tolerability signals

New data from an open-label extension ( SL0008 ) of the EMBLEM phase 2b study evaluating the long-term effects of ...

Leggi articolo

RAI-refractory differentiated thyroid cancer: Sorafenib shows significant improvement in progression-free survival

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced positive data from the phase III DECISION trial investigating the use of ...

Leggi articolo

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase ...

Leggi articolo

Procysbi for management of nephropathic cystinosis : FDA approved

The Food and Drug Administration ( FDA ) has approved Procysbi ( Cysteamine bitartrate ) for the management of nephropathic ...

Leggi articolo

Diclegis for pregnant women with nausea and vomiting: FDA approved

The FDA ( Food and Drug Administration ) has approved Diclegis ( Doxylamine and Pyridoxine ) to treat pregnant women ...

Leggi articolo

Xofigo for advanced prostate cancer, FDA approved

The FDA ( Food and Drug Administration ) has approved Xofigo ( Radium Ra 223 dichloride ) to treat men ...

Leggi articolo

ARISTOTLE subanalysis: efficacy of Apixaban in patients with non-valvular atrial fibrillation

Results from the subanalysis of the ARISTOTLE trial, published in Circulation, have shown that the reductions in stroke or systemic ...

Leggi articolo

Positive CHMP opinion in EU for once-daily, oral Aubagio to treat relapsing-remitting multiple sclerosis

Genzyme, a Sanofi Company, has announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the ...

Leggi articolo

Rhabdomyolysis without the presence of neuroleptic malignant syndrome suspected of being associated with the use of Risperidone

Risperidone ( Risperdal ) is an atypical antipsychotic agent indicated for the treatment or management of schizophrenia, inappropriate behaviour associated ...

Leggi articolo

Tecfidera as a first-line oral treatment for relapsing forms of multiple sclerosis

Biogen Idec has announced that the FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethylfumarate ), a ...

Leggi articolo

Botulism antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes, approved by FDA

The FDA ( Food and Drug Administration ) has announced that it has approved Botulism Antitoxin Heptavalent ( A, B, ...

Leggi articolo

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the ...

Leggi articolo

HIV patients co-infected with hepatitis C virus: Faldaprevir combined with Pegylated Interferon and Ribavirin

Interim study results from STARTverso 4 presented at CROI have shown that 80% of hepatitis C ( HCV ) patients ...

Leggi articolo

Psoriasis: oral Apremilast achieves statistical significance for the primary endpoint of PASI-75 in the ESTEEM 1

The results from ESTEEM 1 for the treatment of psoriasis were presented at the American Academy of Dermatology annual meeting. ...

Leggi articolo

Ultra long-acting beta-adrenoceptor agonist: Olodaterol for maintenance treatment of COPD, recommended for approval

Boehringer Ingelheim has announced that the FDA ( Food and Drug Administration ) Pulmonary-Allergy Drugs Advisory Committee ( PADAC ) ...

Leggi articolo

Anemia drug: Omontys linked to serious and fatal hypersensitivity reactions

The FDA ( Food and Drug Administration ) is alerting health care providers and patients of a voluntary nationwide recall ...

Leggi articolo

PAVES trial: Pegfilgrastim reduces the incidence of febrile neutropenia in patients with colorectal cancer receiving FOLFOX or FOLFIRI and Bevacizumab

PAVES ( Pegfilgrastim and Anti-VEGF Evaluation Study ) trial has evaluated Pegfilgrastim ( Neulasta ) in 845 patients receiving FOLFOX ...

Leggi articolo

Peginterferon beta-1a in relapsing-remitting multiple sclerosis: positive results from ADVANCE trial

Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE. Results support ...

Leggi articolo

Treatment of diabetes in adults: Tresiba and Ryzodeg approved in European Union

Novo Nordisk announced that the European Commission has granted marketing authorisations for Tresiba ( Insulin degludec ) and Ryzodeg ( ...

Leggi articolo

FDA has approved three Alogliptin-based therapies for type 2 diabetes: Nesina, Oseni and Kazano

Takeda Pharmaceuticals has announced that the FDA ( Food and Drug Administration ) has approved Nesina ( Alogliptin ) and ...

Leggi articolo

DECISION Trial: Sorafenib improves progression-free survival in patients with radioactive iodine refractory differentiated thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals have announced that a phase III trial of Nexavar ( Sorafenib ) tablets in patients ...

Leggi articolo

Sirolimus / Tacrolimus more effective than Methotrexate / Tacrolimus in the prevention of grade II-IV acute GVHD and moderate-severe chronic GVHD

There is evidence suggesting that Sirolimus, in combination with Tacrolimus, is active in the prevention of graft-versus-host disease ( GVHD ...

Leggi articolo

Synribo for chronic myelogenous leukemia, FDA approved

The FDA ( Food and Drug Administration ) has approved Synribo ( Omacetaxine mepesuccinate ) to treat adults with chronic ...

Leggi articolo

Post-menopausal osteoporosis: Odanacatib, Cathepsin K inhibitor, increases BMD following prior Alendronate treatment

Merck, known as MSD outside the United States and Canada, has announced results from a phase II trial for Odanacatib, ...

Leggi articolo

Hepatotoxicity remains an important safety concern for all antiandrogen drugs

Antiandrogens are a class of drugs used in androgen deprivation therapy for the treatment of advanced or metastatic prostate cancer. ...

Leggi articolo

Elotuzumab in patients with previously-treated multiple myeloma

Multiple myeloma is the second most common blood cancer and remains incurable despite advances in treatment options over the last ...

Leggi articolo

Seebri Breezhaler as once-daily maintenance treatment for COPD in the European Union

European Commission ( EC ) has approved Seebri Breezhaler ( Glycopyrronium bromide ) 44 mcg delivered dose ( equivalent to ...

Leggi articolo

Afinitor for advanced breast cancer, FDA approved

The FDA ( Food and Drug Administration ) has approved Afinitor ( Everolimus ) for use in combination with Aromasin ...

Leggi articolo

• Successivo →